SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
A phase 1/2 trial of Trastuzumab rezetecan, Bevacizumab, SHR-8068 in cervical cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer is a phase 1/2 interventional study registered as NCT06859775 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 100 participants planned, started 2025-04-25 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A1811, Adebelimab injection, Bevacizumab injection, SHR-8068, Cisplatin injection. Conditions listed: Recurrent or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.
- TrialA Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.
- TrialA Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Cervical cancer.
- TrialSHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals, Bevacizumab, Cisplatin.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares SHR-8068, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Shares SHR-8068, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the
Shares Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin, Cervical cancer.
- TrialA Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals, Bevacizumab.